news

Our latest
Press Releases & Updates

Latest press releases

RetinAI and Retina Consultants of America Join Forces to build the Most Comprehensive U.S.-based Real World Evidence Database in Ophthalmology

RetinAI Medical AG and Retina Consultants of America (RCA) forge a strategic partnership to revolutionize Ophthalmology data. Leveraging RetinAI's advanced AI technologies and RCA's expansive clinic network, this alliance is set to develop the largest Real World Evidence (RWE) U.S.-based database in the field.

RetinAI Joins Forces with Boehringer Ingelheim to Advance Novel Treatments for Patients with Geographic Atrophy using Artificial Intelligence

RetinAI Medical AG has announced a partnership with Boehringer Ingelheim to improve patient outcomes in geographic atrophy (GA). RetinAI's AI tools for identifying novel biomarkers will be used to analyze Boehringer Ingelheim's imaging datasets from clinical studies and real-world evidence to identify additional biomarkers and predictors of disease progression. This partnership aims to accelerate the development of novel treatments and enable earlier and more precise diagnosis, contributing to Boehringer Ingelheim's vision of preventing vision loss and blindness caused by retinal diseases.

RetinAI’s AI Algorithms Enrich Clinical Research and Improve Patient Care

RetinAI Medical AG has announced the acceptance of five abstracts for poster presentations at the Association for Research in Vision and Ophthalmology (ARVO) conference taking place from April 23rd to 26th, 2023 in New Orleans. These studies highlight the potential of RetinAI’s Discovery platform and its certified and research use only (RUO) AI models to revolutionize healthcare decisions, improve patient care, help accelerate clinical trials, and drive better decisions for patient management.

RetinAI and Geographic Atrophy (GA) Expert Working Group partner to enable data collaboration and automated analysis of GA biomarkers for CAM using Discovery

RetinAI partnered with the Classification of Atrophy Meeting (CAM) Group in December 2022 to provide RetinAI’s Discovery® platform to the expert working group, consisting of more than 30 members, to facilitate peer-to-peer data collaboration and perform accelerated, automated biomarker analysis of real-world datasets of geographic atrophy (GA) patients.

Venture Kick Phase III [DECEMBER'17]

Early detection of eye diseases is key for effective treatment to reduce the onset of blindness. However, the patient’s journey to diagnosis is often long and involves many challenges. Venture Kick just awarded RetinAI with 130'000.- CHF to make eye care accessible and affordable to everyone via artificial intelligence.

Read more

5th Medtech & Digital Health Forum Basel [OCTOBER'17]

RetinAI participated in the latest edition of the 5th Medtech & Digital Health Forum in Basel. The team had the opportunity to present our current developments and efforts towards bringing Artificial Intelligence to Ophthalmology, specially in developing countries.

NVIDIA GTC Munich 2017 [OCTOBER'17]

RetinAI held a presentation during the last edition of the Nvidia GTC Europe in Munich, covering how ophthalmology is changing with Machine Learning. Stefanos Apostolopoulos (Technical Director) and Dr. Sandro De Zanet (Scientific Director) presented the efforts the company is doing to improve medical eye care around the world.

‍